SpyGlass Pharma (SGP) Non-Current Assets (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Non-Current Assets of $7.1 million for Q4 2025, up 20.06% year-over-year from $5.9 million in Q4 2024, and up 20.06% quarter-over-quarter from $5.9 million in Q4 2024.
Powered by 
Analysis
SpyGlass Pharma (SGP) Non-Current Assets (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Non-Current Assets for 2 consecutive years, with $7.1 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 468.65 Mn |
| 10 | SpyGlass Pharma | 965.90 Mn | 965.90 Mn | - | 6.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.97 Mn |
| Dec 31, 2025 | 7.10 Mn |
| Dec 31, 2024 | 5.91 Mn |